ConductScience.org, home

Paper17548746

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS and 18 others. Arch Gen Psychiatry, 2007. Cited by 833 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Papers, record 17548746. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17548746

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
PubMed
Journal
Arch Gen Psychiatry
PubMed
Year
2007
PubMed
Publication types
Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
833
iCite
Relative citation ratio, by iCite
25
iCite
Revised in PubMed
2025-11-25
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Keefe RSRichard S E
2Bilder RMRobert M
3Davis SMSonia M
4Harvey PDPhilip D
5Palmer BWBarton W
6Gold JMJames M
7Meltzer HYHerbert Y
8Green MFMichael F
9Capuano GGeorge
10Stroup TST Scott
11McEvoy JPJoseph P
12Swartz MSMarvin S
13Rosenheck RARobert A
14Perkins DODiana O
15Davis CEClarence E
16Hsiao JKJohn K
17Lieberman JAJeffrey A
18CATIE InvestigatorsGroup
19Neurocognitive Working GroupGroup

Source PubMed

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antipsychotic AgentsMajor topic
Cognition DisordersMajor topic
Neuropsychological TestsMajor topic
SchizophreniaMajor topic
Schizophrenic PsychologyMajor topic
Adult
Benzodiazepines
Cohort Studies
Dibenzothiazepines
Double-Blind Method
Female
Humans
Male
Olanzapine
Perphenazine
Piperazines
Quetiapine Fumarate
Risperidone
Thiazoles
Treatment Outcome

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
N01 MH90001NIMH NIH HHSUnited StatesN01MH090001PubMed and NIH

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02634684Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.BackgroundClinicalTrials.gov
NCT06482918Cognitive Remediation in Schizophrenia: Efficacy and Role of Neuroplasticity in "Top-down" and "Bottom-up" MechanismsBackgroundClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17,548,745Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.https://conductscience.org/library/papers/17548745

Source PubMed

Cited by424

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 833 citations.

PMIDTitleJournalYearIn PapersSource
42,936,612Much of the Neurocognitive Impairment in Schizophrenia is Due to Factors Other Than Schizophrenia Itself: Implications for Research and Treatment.Schizophr Bull Open2021https://conductscience.org/library/papers/42936612PubMed
42,920,855Cognitive remediation in schizophrenia: efficacy and role of neuroplasticity in "top-down" and "bottom-up" mechanisms-a randomized, double-blind, treatment-as-usual-controlled study protocol.Front Psychiatry2026https://conductscience.org/library/papers/42920855PubMed
42,793,358Additive Effects of Cognitive Remediation and Physical Exercise in Patients with Schizophrenia: Cognitive Improvements.Brain Sci2026https://conductscience.org/library/papers/42793358PubMed
42,488,869Repetitive Transcranial Magnetic Stimulation (rTMS) as a Modulator of Cognitive Dysfunction in Schizophrenia: Evidence from a Nigerian Outpatient Cohort.Niger Med J2025https://conductscience.org/library/papers/42488869PubMed
42,400,655Effects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis?Eur Arch Psychiatry Clin Neurosci2026https://conductscience.org/library/papers/42400655PubMed
42,383,258Cue-induced inhibitory control in forensic patients with alcohol use disorder: A link to criminal recidivism risk assessed by factor 2 psychopathy.Addict Behav Rep2026https://conductscience.org/library/papers/42383258PubMed
42,253,762Cariprazine augmentation for negative symptoms of schizophrenia: a prospective analysis and literature review.Ther Adv Psychopharmacol2026https://conductscience.org/library/papers/42253762PubMed
42,169,210Cultural adaptation of compensatory cognitive training for Nigerian mental health services: a participatory approach balancing fidelity and contextual fit.Implement Sci Commun2026https://conductscience.org/library/papers/42169210PubMed
41,943,939Dynamic frontoparietal flexibility and cognitive dysfunction in schizophrenia: disentangling the roles of symptom burden and childhood trauma.Psychol Med2026https://conductscience.org/library/papers/41943939PubMed
41,677,693Psychosis: The Utility of Ketamine as a Pharmacological Model of Psychotic-like Symptoms in Rodents: A Review of Dosage Regimens.Biology (Basel)2026https://conductscience.org/library/papers/41677693PubMed
41,629,854Living with psychosis and cognitive impairment: a qualitative study.BMC Psychiatry2026https://conductscience.org/library/papers/41629854PubMed
41,480,735Negative association between cognitive functioning and antipsychotic D2 receptor occupancy, affinity, and dose after first episode psychosis.Psychol Med2026https://conductscience.org/library/papers/41480735PubMed
41,466,278Managing schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensus.Ann Gen Psychiatry2025https://conductscience.org/library/papers/41466278PubMed
41,421,073Neighborhood environmental deprivation predicts the generalized neurocognitive deficit in schizophrenia.Schizophr Res2026https://conductscience.org/library/papers/41421073PubMed
41,373,230Efficacy of Baduanjin Versus Brisk Walking on Cognitive and Physical Functions in Schizophrenia: A Three-Arm Randomized Controlled Trial.Healthcare (Basel)2025https://conductscience.org/library/papers/41373230PubMed
41,281,533Unraveling the mysteries of schizophrenia: Insights into prefrontal cortex dysfunction and therapeutic implications.World J Psychiatry2025https://conductscience.org/library/papers/41281533PubMed
41,121,094Moderating role of familial relationships in the efficacy of rTMS intervention on cognitive function in patients with schizophrenia.BMC Psychiatry2025https://conductscience.org/library/papers/41121094PubMed
40,807,053Targeting Psychotic and Cognitive Dimensions in Clinical High Risk for Psychosis (CHR-P): A Narrative Review.J Clin Med2025https://conductscience.org/library/papers/40807053PubMed
40,711,497Sigma-1 Receptor Activation by Fluvoxamine Ameliorates ER Stress, Synaptic Dysfunction and Behavioral Deficits in a Ketamine Model of Schizophrenia.J Neuroimmune Pharmacol2025https://conductscience.org/library/papers/40711497PubMed
40,341,586The Association Between Psychotropic Medications and Cognitive Functioning in a Real-World Cohort of 869 Individuals with Schizophrenia.Schizophr Bull2026https://conductscience.org/library/papers/40341586PubMed

See all 424 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17548746

GET https://conductscience.org/api/papers/v1/17548746/cited_by?page=2